Literature DB >> 31740982

[Durvalumab after radiochemotherapy for locally advanced unresectable NSCLC-a breakthrough].

Matthias Guckenberger1.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 31740982     DOI: 10.1007/s00066-019-01545-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  18 in total

1.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Authors:  Miklos Pless; Roger Stupp; Hans-Beat Ris; Rolf A Stahel; Walter Weder; Sandra Thierstein; Marie-Aline Gerard; Alexandros Xyrafas; Martin Früh; Richard Cathomas; Alfred Zippelius; Arnaud Roth; Milorad Bijelovic; Adrian Ochsenbein; Urs R Meier; Christoph Mamot; Daniel Rauch; Oliver Gautschi; Daniel C Betticher; René-Olivier Mirimanoff; Solange Peters
Journal:  Lancet       Date:  2015-08-11       Impact factor: 79.321

2.  Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Authors:  S Peters; U Dafni; M Boyer; D De Ruysscher; C Faivre-Finn; E Felip; P Garrido; N Girard; M Guckenberger; J Haanen; C Le Pechoux; F Mornex; M Ozsahin; L Paz-Ares; D Planchard; D Raben; S Ramalingam; M Reck; E Smit; R Stahel; A Stenzinger; C Swanton; S Vallone; M C Garassino
Journal:  Ann Oncol       Date:  2019-02-01       Impact factor: 32.976

3.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

6.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544

7.  Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Authors:  Ariel E Marciscano; Ali Ghasemzadeh; Thomas R Nirschl; Debebe Theodros; Christina M Kochel; Brian J Francica; Yuki Muroyama; Robert A Anders; Andrew B Sharabi; Esteban Velarde; Wendy Mao; Kunal R Chaudhary; Matthew G Chaimowitz; John Wong; Mark J Selby; Kent B Thudium; Alan J Korman; David Ulmert; Daniel L J Thorek; Theodore L DeWeese; Charles G Drake
Journal:  Clin Cancer Res       Date:  2018-06-13       Impact factor: 12.531

8.  Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Authors:  Christina Twyman-Saint Victor; Andrew J Rech; Amit Maity; Ramesh Rengan; Kristen E Pauken; Erietta Stelekati; Joseph L Benci; Bihui Xu; Hannah Dada; Pamela M Odorizzi; Ramin S Herati; Kathleen D Mansfield; Dana Patsch; Ravi K Amaravadi; Lynn M Schuchter; Hemant Ishwaran; Rosemarie Mick; Daniel A Pryma; Xiaowei Xu; Michael D Feldman; Tara C Gangadhar; Stephen M Hahn; E John Wherry; Robert H Vonderheide; Andy J Minn
Journal:  Nature       Date:  2015-03-09       Impact factor: 49.962

9.  DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

Authors:  Claire Vanpouille-Box; Amandine Alard; Molykutty J Aryankalayil; Yasmeen Sarfraz; Julie M Diamond; Robert J Schneider; Giorgio Inghirami; C Norman Coleman; Silvia C Formenti; Sandra Demaria
Journal:  Nat Commun       Date:  2017-06-09       Impact factor: 14.919

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.